Biogen (BIIB) Payables (2009 - 2026)

Biogen has reported Payables for 18 years, with the latest figure at $403.9 million in Q2 2026.

• On a quarterly basis, Payables fell 1.1% year-over-year to $403.9 million in Q2 2026; TTM through Jun 2026 was $403.9 million, a 1.1% decrease from a year earlier, with the FY2025 full-year figure at $432.0 million, down 80.12% from the prior year.
• Payables was $403.9 million for Q2 2026 at Biogen, up from $358.5 million in the prior quarter.
• The five-year high for Payables was $2.2 billion in Q4 2024, with the low at $354.5 million in Q2 2024.
• Average Payables over 5 years is $868.3 million, with a median of $491.4 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Payables jumped 292.7% in 2024, then plunged 83.25% in 2026.
• Over 5 years, Payables stood at $491.5 million in 2022, then climbed by 12.57% to $553.3 million in 2023, then surged by 292.7% to $2.2 billion in 2024, then sank by 80.12% to $432.0 million in 2025, then fell by 6.5% to $403.9 million in 2026.
• The last three Payables figures came in at $403.9 million (Q2 2026), $358.5 million (Q1 2026), and $432.0 million (Q4 2025), per Business Quant data.